Cronos Group shows genuine 40% YoY revenue growth, a strong Piotroski F-Score, and bullish above-200-day-MA technicals, but a quality score below the engine's minimum floor and a deeply negative asymmetry ratio drive an explicit exit recommendation.
Thesis pillars
- Revenue Growth Leadership→Stable
- Piotroski Quality Signal→Stable
- Negative Asymmetry Target Reached→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 5, 2026, based on the 10-K filed Feb 26, 2026
Cronos Group Inc. Common Share (CRON) Stock Analysis
Range Bound setup
Healthcare · Drug Manufacturers - Specialty & Generic
Wait for pullback to $2.85. Price sits above the model's entry target of $2.85; the risk/reward becomes favorable on a pullback. Key risks: Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.7).
Cronos Group is a cannabinoid company selling cannabis products under the Spinach, PEACE NATURALS, LIT, and Lord Jones brands, with licensed cultivation and processing in Ontario, Canada and Israel. Two customers — Ontario Cannabis Retail Corporation and Alberta Gaming, Liquor... Read more
Wait for pullback to $2.85. Price sits above the model's entry target of $2.85; the risk/reward becomes favorable on a pullback. Key risks: Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.7). Chart setup: RSI 57 mid-range, Bollinger mid-band. Earnings in 2 days. Wait until post-earnings. Score 6.4/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 2d<=7d. Suitability: aggressive.
About Cronos Group Inc. Common Share
About Cronos Group Inc. Common Share
Cronos Group sells cannabis products under the Spinach, PEACE NATURALS, LIT, and Lord Jones brands from a single reporting segment spanning licensed production in Canada and Israel. Two customers, Ontario Cannabis Retail Corporation and Alberta Gaming, Liquor and Cannabis Commission, accounted for approximately 27% and 16% of consolidated net revenues in 2025, and Cronos sold $122.4 million of product to Canadian cannabis control authorities during the year.
Cronos cultivates and processes cannabis at the Peace Naturals Campus in Ontario and through Cronos GrowCo, a 50%-owned joint venture over whose board Cronos gained majority control in July 2024 and which the company describes as its principal cannabis source; Cronos holds the right, but not the obligation, to purchase up to 70% of GrowCo's total production. In Israel, Cronos Israel distributes PEACE NATURALS and LIT medical cannabis through pharmacies under IMC-GAP, IMC-GMP, and IMC-GDP certifications, and the company has expanded LIT and Lord Jones distribution into Germany and the United Kingdom through third-party partners. Altria Group beneficially owned 41.0% of Cronos common shares as of December 31, 2025 and holds board-nomination, approval, and pre-emptive rights under an investor rights agreement tied to its ownership threshold.
Show full overview
Cronos does not engage in any U.S. Schedule I cannabis activity, insulating it from federal enforcement risk that touches U.S.-domiciled operators, even after President Trump's December 18, 2025 executive order directed the Attorney General to expedite rescheduling marijuana to Schedule III — a change that would not take effect until the required federal rulemaking process concludes. Government-channel dependency is the more immediate exposure: Canadian sales flow through provincial cannabis control authorities that can renegotiate prices or terminate supply agreements at their election, concentrating Cronos's two largest customer relationships within government-run distribution monopolies rather than diversified retail accounts.
See also: Healthcare · Drug Manufacturers - Specialty & Generic
From Cronos Group Inc. Common Share's most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-11-02Recent Developments — Cronos Group Inc. Common Share
Latest news
- NEWS CRON Q2 2026 Earnings: EPS of $0.09 Tops a Zero Estimate as Shares Rise 2.11% - Earnings Manipulation Risk - dars.gov.et — dars.gov.et positive
- NEWS Cronos Group Surges as Record Q2 Fuels Cannabis Turnaround Story - kalkine.ca — kalkine.ca positive
- NEWS Cronos Group Inc. stock rises Wednesday, outperforms market - MarketWatch — MarketWatch positive
- NEWS Cronos Group Inc. stock rises Wednesday, outperforms market - marketwatch.com — marketwatch.com positive
- NEWS Cronos Group Inc. stock falls Wednesday, underperforms market - MarketWatch — MarketWatch negative
Generated 2026-11-02T11:33:16Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomerOntario Cannabis Retail Corporation27%10-K Item 1: 'there were two major customers, Ontario Cannabis Retail Corporation and Alberta Gaming, Liquor and Cannabis Commission, which accounted for approximately 27% and 16%, respectively'
- LOWCustomerAlberta Gaming, Liquor and Cannabis Commission16%10-K Item 1: 'there were two major customers, Ontario Cannabis Retail Corporation and Alberta Gaming, Liquor and Cannabis Commission, which accounted for approximately 27% and 16%, respectively'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $2.85. Price sits above the model's entry target of $2.85; the risk/reward becomes favorable on a pullback. Key risks: Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.7). Chart setup: RSI 57 mid-range, Bollinger mid-band. Earnings in 2 days. Wait until post-earnings. Analyst target $2.57 reached (−22.1%), stop $2.65 (−24.5%), A.R:R -3.7:1. Score 6.4/10, moderate confidence.
Analyst target $2.57 reached (−22.1% from $3.30); no take-profit level is published. Analyst target $2.57 reached (−22.1%), stop $2.65 (−24.5%), A.R:R -3.7:1. Stop-loss: $2.65.
Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.7); Value-trap signals (3/5): Revenue declining (-42.3% YoY), Margin compression (op margin -4043.8%), Negative free cash flow.
Cronos Group Inc. Common Share trades at a P/E of 17.4 (forward -82.5). TrendMatrix value score: 4.3/10. Verdict: Buy (Wait for Entry).
10 analysts cover CRON with a consensus score of 4.1/5. Average price target: $3.
What does Cronos Group Inc. Common Share do?Cronos Group is a cannabinoid company selling cannabis products under the Spinach, PEACE NATURALS, LIT, and Lord Jones...
Cronos Group is a cannabinoid company selling cannabis products under the Spinach, PEACE NATURALS, LIT, and Lord Jones brands, with licensed cultivation and processing in Ontario, Canada and Israel. Two customers — Ontario Cannabis Retail Corporation and Alberta Gaming, Liquor and Cannabis Commission — accounted for approximately 27% and 16% of consolidated net revenues in 2025, and Altria Group holds a 41.0% equity stake with board and governance rights.